Literature DB >> 1822077

Prognostic significance of proteinuria one year after onset of diarrhea-associated hemolytic-uremic syndrome.

D V Milford1, R H White, C M Taylor.   

Abstract

We examined the prognostic value of changes in the amount of proteinuria, measured as protein/creatinine ratios in early-morning urine samples, in 40 children who had had diarrhea-associated hemolytic-uremic syndrome. One year after diagnosis, 87% of those who seemed to have fully recovered had normal urinary protein/creatinine ratios, compared with none of those with poor outcomes (p less than 0.001). None of those with poor outcomes achieved normal protein/creatinine ratios during follow-up to a maximum of 5 1/2 years, but 93% of those who made a full clinical recovery no longer had proteinuria. Measurement of the protein/creatinine ratio in an early-morning sample of urine is a simple, cost-effective, and noninvasive means of monitoring the progress of patients with diarrhea-associated hemolytic-uremic syndrome, provided that a technique sensitive at low protein concentrations is employed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1822077     DOI: 10.1016/s0022-3476(05)80481-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome.

Authors:  Randall Lou-Meda; Robert S Oakes; Jarom N Gilstrap; Christopher G Williams; Richard L Siegler
Journal:  Pediatr Nephrol       Date:  2006-09-12       Impact factor: 3.714

2.  Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.

Authors:  Maria Gracia Caletti; Mabel Missoni; Clarisa Vezzani; María Grignoli; Juan Jose Piantanida; Horacio A Repetto; Ramon Exeni; Stella Maris Rasse
Journal:  Pediatr Nephrol       Date:  2011-04-30       Impact factor: 3.714

3.  Prognosis of motor development and joint hypermobility.

Authors:  E Tirosh; M Jaffe; R Marmur; Y Taub; Z Rosenberg
Journal:  Arch Dis Child       Date:  1991-08       Impact factor: 3.791

4.  Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component.

Authors:  Anne K Dettmar; Elisabeth Binder; Friederike R Greiner; Max C Liebau; Christine E Kurschat; Therese C Jungraithmayr; Moin A Saleem; Claus-Peter Schmitt; Elisabeth Feifel; Dorothea Orth-Höller; Markus J Kemper; Mark Pepys; Reinhard Würzner; Jun Oh
Journal:  Infect Immun       Date:  2014-02-24       Impact factor: 3.441

5.  Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.

Authors:  María Gracia Caletti; Alejandro Balestracci; Mabel Missoni; Clarisa Vezzani
Journal:  Pediatr Nephrol       Date:  2012-12-20       Impact factor: 3.714

6.  Urinary protein/creatinine index in follow up of patients with Wilms' tumour after nephrectomy.

Authors:  C Mpofu; J R Mann
Journal:  Arch Dis Child       Date:  1992-12       Impact factor: 3.791

Review 7.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

8.  Long term renal outcome of childhood haemolytic uraemic syndrome.

Authors:  M M Fitzpatrick; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  BMJ       Date:  1991-08-31

9.  Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.

Authors:  Catherine Monet-Didailler; Astrid Godron-Dubrasquet; Iona Madden; Yahsou Delmas; Brigitte Llanas; Jérôme Harambat
Journal:  Pediatr Nephrol       Date:  2018-10-27       Impact factor: 3.714

10.  Nephrotic-range proteinuria and central nervous involvement in typical hemolytic uremic syndrome: a case report.

Authors:  Chuan Shi; Chao Li; Wei Ye; Wen-Ling Ye; Ming-Xi Li
Journal:  BMC Nephrol       Date:  2020-07-31       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.